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INTRODUCTION 
 
“For all the happiness mankind can gain is not in pleasure, but 
in rest from pain” 
       John Dyrden 
  
The relief of pain during surgery is the raison d’etre of anaesthesia.  Pain is a 
fundamental biological phenomenon. The aim of anaesthesiology as a science is the 
removal of pain temporarily, started initially with pain relief for surgeries, and now extends to 
post operative pain relief, relief of chronic pain, and cancer pain. 
 Effective post operative analgesia reduces post operative morbidity, allows early 
ambulation and discharge.  Post operative analgesia is achieved by various techniques 
using various drugs among which neuraxial blockade plays  an important role. 
 The accidental entry of corning’s needle in 1885, in to the subarachnoid space paved 
the way for the greatest leap into spinal anaesthesia.  His words “Be the destiny of this 
observation, what it may, has seemed to me on the whole worth recording..,” opened the 
prologue. The word spinal anaesthesia was coined by him. 
 
 
History of Pain 
  An anesthesiologist has a role to relieve pain due to various causes including post 
operative pain. 
Pain – The word derived from a Greek word “poine” which means penalty. 
Pain is defined as an unpleasant sensory and emotional experience which is associated with 
actual tissue damage or potential of tissue damage or at least described in terms of such 
damage. 
Aristotle – Described that the pain was an emotion emanating from the heart. 
Galen – Correctly observed brain was required to manifest the pain and he also proposed 
that sensation is a property of nervous tissue.  
The idea of specific neural pathways for painful sensations began with CHARLES 
BELL (1774-1842) and FRANCOIS MAGENDIE (1783-1855) who both demonstrated that 
dorsal roots of the spinal cord transmit sensory informations and the ventral root transmit the 
motor informations. 
In 1948 Ahlquist proposed the designations of α and β receptors. Since then various 
subtypes of these two main classes have been characterized. Various theories regarding 
pain transmission including gate control theory (1965) by Melzack and Wall. Endogenous 
opioids are located at diverse sites in the pain pathway, including dorsal horn of influence 
rostral transmission of Pain. By using intrathecal or epidural injection, the nociceptive 
transmission at the 1st synaptic relay in the spinal cord may be manipulated. 
The α2 adrenergic mechanisms have been exploited for more than hundred years.  
Cocaine, the first spinal anesthetic primarily produces analgesia by its local anesthetic 
properties and also in which nor-adrenaline re-uptake, in part by increasing noradrenergic 
stimulation of α2 receptors. Veterinarians have used α2 agonists (Detomidine, Meditomidine) 
for many years for regional analgesia, but experience with these agents in humans, dates 
back only slightly more than ten years. 
In 1984 Tamsen, Gordh after testing neuro toxicity in animals and then injected a 
parental preparation of α2 agonist Clonidine, epidurally in two patients with chronic pain.  
Since then the complete toxicologic assessment in animal studies has suggested that 
Clonidine is safe for intrathecal use.1 
 
Physiology of pain 
  Pain is a complex phenomenon and includes both  
 sensory – discriminative and  
 motivational – affective components 
Sensory –discriminative component:   
This component depends upon the ascending projection of tracts like spinothalamic 
and trigeminothalamic tracts into the cerebral cortex.  Thus they help to perceive the quality 
of pain that is pricking, burning quality etc. They also help to know the location of stimulus, 
intensity and duration of the stimulus. 
Motivational - affective component:  
 It includes attention, arousal, somatic, autonomic reflexes, endocrine and emotional 
changes. These collectively contribute to the unpleasant nature of pain. 
 
 
Pain receptors: (Nociceptors)   
 These are the free nerve endings present in the skin, muscles, joints, viscera, and in 
the vasculature.  Theses receptors detects the noxious stimulus due to the chemical, thermal 
(heat, cold) and mechanical changes.  In normal tissues they are inactive and are stimulated 
by a sufficient energy to overcome their resting threshold.  Thus they prevent random signal 
propagation to central nervous system for interpretation of pain. This is so called screening 
function.  The nociceptive neurons synapse in the dorsal horn of the spinal cord with both 
local interneurons and projection neurons that carry the nociceptive information to the higher 
centers present in the brainstem, thalamus.  In contrast to the   other sensory receptors “ 
the pain receptors do not adapt “ and this unique feature is protective and thus allows the 
individual to aware of continued tissue damage.  After damage, pain is usually minimal and 
also the onset pain depends upon the rate of metabolism. e.g. ischemic injury of the skin 
usually produces pain with 20 to 30 minutes, but for the exercising muscles the pain occurs 
within 15 to 20 seconds.  Certain specific types of nociceptors reacts only to the specific 
stimuli, but other nociceptors react to multiple stimuli for e.g. “ C “ nociceptors and  A delta 
nociceptors reacts to heat or cold stimuli.  Some Aβ receptors which are usually 
mechanoreceptors may have nociceptor like activity. Aβ mechanoreceptor sensory fibers 
can be recruited to transmit signals that will interpret as painful stimuli. But it occurs only 
when these receptors are in the environment of inflammation. The mechanical allodynia 
(painful sensation results from light touch) results from Aβ receptors recruitment. 
Visceral receptors:   
 These are not designed solely as pain receptors because the internal organs are not 
frequently exposed to potentially damaging events.  Many damaging events like cutting,  
burning, clamping the visceral organs do not produce pain but the ischemic injury, 
inflammation, dilation, spasm of hollow organ and stretching  of the mesentery produces 
pain. 
 
Neurobiology of pain 
 The experience of pain involves a series of complex physiologic processes which 
includes four components. They are 
A) Transduction: is the process by which the noxious stimuli is converted in to an 
electrical impulse in sensory nerve endings. 
B) Transmission:  Is the process by which these electrical impulses are conducted to 
central nervous system through the connections in the dorsal horn of the spinal cord 
and thalamus with projections to the cingulated, insular and somatosensory cortexes. 
C) Modulation: Is the process of altering the pain transmission that is both inhibitory and 
excitatory mechanisms present in the peripheral nervous system and central nervous 
system. 
D) Perception: Is thought to occur at thalamus and the cortex is important for the 
discrimination of specific sensory experiences.   
Pain may occur even in the absence of any of these above four steps. For example pain due 
to trigeminal neuralgia occurs in the absence of transduction of chemical stimulus at 
nociceptor. 
Modulation may be absent if specific nervous system tracts are injured for example - 
phantom limb pain occurs in the absences of nociceptors. 
 
Transduction: 
 When the resting thresholds of the sensory nerve endings are exceeded by 
mechanical, chemical or thermal changes, these mechanical or chemical changes or 
converted into an electrical action potential and is transmitted to the spinal cord. Nociceptors 
generates action potential that results in the perception of pain before tissue damage occurs 
(protective). A delta and “C” fibers undergo peripheral sensitization when they are exposed 
to inflammatory mediators, so that their firing thresholds decrease, but their firing is 
increased with increased intensity and duration. But in majority of the cases when acute 
inflammation subsides, this process naturally resolves and peripheral sensitization decrease 
and the nociceptors returned to their original resting threshold. But in chronic pain they do 
not return to the original resting threshold which results in the persistent pain sensation and 
presents as allodynia or hyperalgesia.  
Transmission:    
 Pain signals transmitted from the nociceptive receptors along the myelinated A δ 
fibers (which is responsible for rapid conduction and early response) and unmyelinated “C” 
fibers (which is responsible for slow conduction and delayed response). These fibers enter 
the spinal cord through dorsal nerve root and terminate on the cells in the dorsal horn. 
 
 
Modulation:   
Peripheral modulation:    
 Occurs by liberation or elimination of chemicals near the nociceptor.  Tissue injury 
activates nociceptor in the periphery by releasing neurotransmitters like substance P, 
glutamate that directly activate nociceptors.  Other mediators like bradykinin, prostaglandin 
further sensitizes and excites the receptors and also acts as mediators of inflammation. 
Ischemic injured cells, mast cells, plasma, platelets surrounding the receptors are the 
sources of these mediators.  Drugs like NSAID by inhibiting the prostaglandin synthesis may 
influence the peripheral modulation, but Clonidine has no role at the periphery. 
Spinal modulation: 
 It occurs due to actions of neurotransmitters at dorsal horn or from spinal reflexes 
which convey the efferent impulses back to the peripheral nociceptive field. Glutamate, 
aspartate, neuropeptide Y are the excitatory substances involved in the regulation of pain 
transmission. GABA, glycine, noradrenaline are inhibitory substances involved in the pain 
transmission. Clonidine has a role at dorsal horn of the spinal cord. 
Supraspinal modulation: 
Includes endogenous narcotics and monoamine pathways which have cell bodies 
situated around the periaqueductal greymatter and these are the descending inhibitory 
pathways. They descend in to the dorsolateral fasciculus and synapse in the dorsal horn. 
Neurotransmitters act pre-synaptically on first order neuron and post-synaptically on second 
order neurons in the spinothalamic tract. Analgesia is produced by electrical stimulation of 
the peri-aqueductal gray matter. Neurotransmitters released from these projections 
hyperpolarize the A delta fibers and C fibers that serve to negate depolarizing currents that 
approach the terminal endplates and thus diminishing the release of neurotransmitters like 
suptance P. Hyperpolarization of nerves most likely occurs because of the opening of 
potassium ion channels and inhibition of calcium ion movement. 
 Cognitive modulation:  
This involves the patient’s ability to relate a painful experience to another event, so 
that the pain experienced in pleasant environment is less intense than that experienced in 
the setting of depression. Another area of perception is attention which allows only fixed 
number of afferent impulses to the cortical centers, so that, if the patient concentrate on 
separate unrelated thing, it is possible to decrease the painful sensations (biofeedback or 
hypnosis).  
 
Dorsal horn and ascending nociceptive pathways 
  Primary afferent fibers with their cell bodies in the dorsal root ganglion which is 
connected second neuronal cell located in the dorsal horn. Afferent fibers from the peripheral 
receptors enters the spinal cord then ascend and descend  several segments in the lissauer 
tract in the dorsal horn. 
Dorsal horn of the spinal cord    contains six laminae 
            Laminae I and II   are the sites of termination of afferent C fibers and these two 
laminae collectively known as substantia gelatinosa which is important for integration and 
modulation of incoming nociceptive information. 
           Laminae V is the site which receives the input from both nociceptive and non-
nociceptive neurons. Second order wide dynamic range neurons (W.D.R) neurons, 
nociceptive specific neurons terminate here. The nociceptive specific neurons respond only 
to nociceptive stimulus.  WDR neuron responds to both non-nociceptive and nociceptive 
stimuli.  Both types of neurons are believed be important in the perception of nociceptive 
information. Chronic pain conditions are explained in terms of the input to these cells and 
their supraspinal connections.  
 NeuroPlasiticity: 
 Neuroplasticity describes the dynamic modulation of the neural impulses.  As the 
peripheral nerve firing increases there is some functional changes also occurs in the 
excitability of spinal cord neurons and altering their responses to afferent impulses. 
 
Wind-up phenomenon: 
 The temporal summation of number and duration of action potentials elicited per 
stimulus that occurs in the dorsal horn neurons has been referred to as wind-up 
phenomenon.  This result in persistence of action potential for up to sixty seconds after 
stopping the stimulus and results in change in spinal cord processing that can lasts for one 
to three hours. Spinal cord synaptic plasticity involves binding of glutamate to NMDA 
receptors as well as substance P and neurokinins. Binding of glutamate to NMDA receptors 
alters magnesium dependent block of iron channels , which increases permeability to all 
cations particularly Na+, Ca2+ , furthermore glutamate activates AMPA receptors which  
control depolarization primarily through modulation of  Na+ influx into cells. In addition 
to modulating augmented excitability these transmitters, cellular mechanism mediate 
changes in postsynaptic cells leading to permanent changes in nerve conduction.   
 
Transmission and modulation: 
 Dorsal horn and its laminae act as receiving site action potential coming from 
periphery via primary afferent neurons.  The primary afferents terminates in the dorsal horn 
and synapse with secondary afferent neurons. The secondary afferent neurons act as gate 
cells providing initial modulation of action potentials in the dorsal horn. Two main classes of 
neuro-transmitters associated with primary afferent nociceptive transmission in the dorsal 
horn 
1. Excitatory amino acids e.g., Glutamate  
2. Neurokinin  peptides e.g., Substance P  
Perception: 
Thalamus and cortex:  
 After leaving the dorsal horn nociceptive action potentials ascends through  
spinothalamic tract , spinocervical tracts , Spino reticular tracts and spino mesencephalic 
tracts and reach higher centers like cerebral cortex , hypo thalamus reticular formation and 
mid brain. Afferent impulses to reticular area and activates this area which then send signals 
through thalamus and cerebral cortex.  This alerts the individual to continuous tissue 
damage and awakens the person from sleep.  These signals are poorly localized and helps 
only to alert the individual.  
 
NMDA receptors : 
 NMDA receptors are postsynaptic to primary afferent neuron and located on 
secondary afferent neurons.  They are blocked by Mg2+ ions under normal conditions the 
secondary afferent neurons are not depolarized along enough to dislodge the mg2+ ions from 
the ion channels to permit ca2+ ions. Glutamate rapidly removed from the synaptic cleft and 
there is no activity at NMDA receptors in normal nociceptive transmission.  But in the 
presence of pain arising from abnormal conditions like neuropathic pain, chronic pain 
peripheral sensitization, the frequency of pain signals increase as which in turn increases the 
amount glutamate.  This glutamate depolarize the secondary afferent neuron long enough to 
dislodge the Mg2+ which blocking the NMDA receptors. Subsequent activation NMDA 
receptors acts to activate second messengers , enzyme systems and various substances 
like nitric oxide that contributes to enhanced sensitivity known as central sensitization . The 
activation of NMDA by glutamate also activates protein kinase-C, which causes uncoupling 
of opioid receptors system results in decreasing responsiveness which is called opioid 
tolerance.  
 
Types of pain: 
 Qualitatively there are two types of pain  
 
1. Fast pain - is short, well localized, stabbing sensation that is matched to the stimulus like 
in pin prick, surgical incision. This pain starts abruptly when the stimulus is applied and stops 
when the stimulus is removed. This is due to stimulation of small myelinated   A δ fibers with 
conduction velocities of 12 to 30 m/s.  Myelination provides junctions that permit the 
electrical impulses to jump which results in rapid transmission.  
 2. Slow pain- is throbbing, burning or aching sensation that is poorly localized  and poorly 
matched to  stimulus . This is due to stimulation of unmyelinated  C -fibers with conduction 
velocity of 0.5 to 2 m/s. 
 
 
 
 
 
Clonidine 
Pharmacology and Pharmacodynamics   
  
It is a 2, 6 - dichloro phenyl - 4, 5 dihydro- 1H-imidazol-2 amine with formula 
C9H9Cl2N3. It is an imidazoline derivative and acts on both α1 and α2 receptors with ratio of α2 
and α1 are 220:1. It stimulates α2 receptors both at central and peripheral sites. It is not a 
pure α2 agonist and it also acts on non-adrenergic imidazoline preferring receptors.  
 
 
  
 
Sub types of α2 receptors: 
1) α2A 2) α2B and  3)α2C 
α2A - mediates sedation, sympatholysis, analgesia  
α2B - vasoconstriction, anti-shivering mechanism  
α2C - Sturtle response.  It is the response of the body and mind to sudden unexpected stimuli 
e.g. a flash of light. 
 
 
Mechanistic information: 
α2 receptors are located on primary afferent terminals ( both  peripheral and spinal 
endings) on neurons in superficial laminae of the spinal cord and within the brainstem nuclei 
implicated in analgesia9 , supporting the possibility of analgesic  action at periphery , spinal 
and brainstem sites. Notably the axons of peripheral nerves or lacking the α2 receptors , but  
Clonidine produces minor degree of  conduction blockade at higher concentration with some 
preference to ‘C’ fibers10,11 .  This action may underlie in part, in the enhancement of 
peripheral nerve block when this agent added to the local anesthetics. 
  
Analgesia produced by intrathecal Clonidine is not produced by systemic absorption 
because the peak levels in arterial blood is achieved within 10 minutes and in intravenous 
blood is within 30 to 45 minutes elimination from the blood is slow and the duration analgesia 
is relatively brief and this point is arguing against an action by systemic absorption and 
redistribution to central and peripheral sites. 
 
Various routes of administration and dosage 
 
ROUTE DOSE 
intra nasal 2 – 4μg/kg 
intramuscular 2 μg/kg 
oral 4 – 5μg/kg 
Intravenous Bolus: 1 - 2μg/kg 
Infusion: 0.18—3.16 μg   
Rectal 2.5 - 5 μg/kg  
with atropine 50 μg/kg 
Caudal 1 - 2 μg/kg 
Spinal adjuvant 1 - 2 μg/kg 
Epidural adjuvant 0.0625% bupivacine  with  fentanyl 1 μg/ml and  
clonidine 0.6μ/ml at  a rate of 0.2 ml/kg/hr 
Sciatic nerve block 0.2% ropivacine 0.4 mg/kg/hr with  
clonidine 0.12 μg/kg/hr as infusion 
Para vertebral block 19ml bupivacine  as a bolus with  
Clonidine 150 μg/kg given  every 48 hours for 3 weeks via catheter
 
 
 
 
Comparison between various routes of administration: 
As with lipophilic opiods the Clonidine produces it’s effect after intravenous, 
intrathecal, epidural administration but more potent after neuraxial administration than after 
systemic administration ,this point supporting the spinal site of action of the Clonidine and 
thus favouring the neuraxial administration of the Clonidine. This is confirmed by one study 
in which small dose of Clonidine (150μg) in intrathecal route provides 4 - 6 hrs of analgesia 
in case of caesarean section or minor orthopedic surgery, but the same dose of Clonidine by 
intramuscular route or epidural route produces no more analgesia than placebo.15,16 
 
Comparison of epidural and intravenous routes of administration: 
Larger dose of Clonidine through epidural administration produces better analgesia 
and accompanied by 50% reduction in morphine requirements. These results are in 
accordance with spinal site of action15,16  
 In second type of study, the patients were allowed to titrate the drug to get a similar degree 
of pain relief via PCA to compare the potency of the drug by different routes of 
administration. By using this method Bernard and colleagues18 recently demonstrated the 
Clonidine is approximately 2 times more potent in epidural route than intravenous.  
 
Confirmation of the receptor site: 
  Yohimbine, an α2 antagonist produces at least partial reversal of epidural analgesia 
and sedation although the effects on blood pressure and heart rate were not reversed19.   
Acetylcholine and neuraxial Clonidine: 
 Epidurally administered Clonidine produces increase in a release of acetylcholine in 
the dorsal horn of the spinal cord, but not in the ventral horn. 
Analgesia produced by the epidural Clonidine in volunteers is enhanced by the intrathecal 
injection of choline-esterase inhibitor neostigmne. This interaction is additive only in humans, 
but synergistic in animals. This supports the cholinergic mechanism in spinal analgesia 
produced by the Clonidine. The descending nor-adrenergic pathways release nor-adrenaline 
to cause analgesia directly and by stimulating the  release of acetylcholine.12,23  
Clonidine and local anaesthetics:              
 Clonidine enhances both sensory and motor blockade produced by the local 
anaesthetics by three possible mechanisms 
1. Clonidine blocks the conduction in the “C” fibers and in the “Aδ” fibers and increases the 
K+ ion conductance in isolated neurons in-vitro and it intensifies the conduction blockade 
produced by the local anesthetics, because the systemic pharmacokinetics are not the factor 
in vitro experiments. These data supports the direct effect of the Clonidine on neural 
transmission in high local concentration. 
2. Clonidine may produce vasoconstriction and thereby inhibiting the removal of the local 
anaesthetics surrounding the neural tissues, but this occurs only in high concentrations and 
there is little evidence for this mechanism with clinically used concentrations and this is 
confirmed by the observation that the plasma lignocaine concentrations is same with or 
without Clonidine addition, but this plasma lignocaine concentrations is reduced because of 
decreased systemic absorption10, 11, 24 . 
Hemodynamic effect:                                                                   
 Clonidine is lipophilic so that there is rapid and extensive systemic absorption 
following spinal administration and the hemodynamic effects are in part ,due to it’s actions at 
both central and peripheral nervous system. It affects blood pressure in a complex manner 
because it has opposing actions at multiple sites.28,29 
1. In the nucleus tractus solitarius and locus cerulius of the brain stem the Clonidine causes 
activation of post synaptic α2 noradrenergic receptors and reduces the sympathetic drive. 
2. It is not a pure α²/α1 agonist, and also it activates non-adrenergic imidazoline preferring 
receptors which are present in the lateral reticular nucleus and thereby producing 
hypotension and anti-arrythmic action30,31.   
3. In the peripheral nervous system it activates α sub2 adrenoceptors at sympathetic 
terminals and reduces nor-adrenaline release from these terminals ,which could cause vaso 
relaxation and reduces the chronotropic drive. These brainstem and peripheral α2 
adrenoceptor stimulation are counterbalanced by direct peripheral vasoconstriction from 
circulating concentrations of α²/α1adnergic agonist, clonidine.32 
In addition to the brainstem, peripheral sites of actions the neuraxial administration of 
the clonidine directly inhibits the pre-ganglionic sympathetic neurons in the spinal cord33  
especially in the upper thoracic level of injection (which produces  more profound 
hypotension )34,35 but at the lower thoracic level of administration, Clonidine is not associated 
with increased incidence of hypotension17.  Increased incidence with upper thoracic injection 
perphaps reflects the rostrocaudal gradient of noradrenergic innervation of sympathetic pre-
ganglionic fibers. 
 
Action of the clonidine on myocardial proformance:   
I)  Produces bradycardia partly due to vagomimetic action and partly due to pre-synaptically 
mediated inhibition of nor-adrenaline release at neuroceptor junction Although it depresses 
the AV nodal conduction, severe brady arrythmias are rare with Clonidine. 
II) It increases the cardiac output by reducing the afterload, but in some partients, it reduces 
cardiac output due to the decrease in the heart rate. 
III) It reduces the Oxygen demand and has been shown to reduce the infarct size when 
administered to the patients in the acute phase of myocardial infarction.  Haemodynamic 
effects after neuraxial or systemic administration starts within 30 minutes and reaches the 
maximum effect within 1 to 2 hours   and lasts for approximately 6 to 8 hours after single 
injection. Delayed onset of hypotension has not been observed with the use of Clonidine for 
analgesia alone or in combination.36 
Hemodynamic effects: 
 This combination produces higher degree of sympatholysis and the combination of 
Clonidine and local anesthetics in neuraxial route and resulting hypotension is also  high. 
Clonidine has minor or no effects on responses to vasoconstrictors or atropine given to treat 
hypotension or bradycardia that may occur with neuraxial anesthesia36. Clonidine pre-
treatment delays the central nervous system or cardiovascular system toxic manifestations 
of Bupivacaine overdose and also it improves ventricular electrophysiologic parameters in 
dogs.  But this is not to imply that Clonidine should be used as treatment for Bupivacaine 
overdose, but rather to emphasize that, should such overdose occur, inclusion of Clonidine 
is unlikely to exacerbate the problem. Spinal neostigmine counteracts the hypotension 
induced by Clonidine due to cholinergically mediated increase in pre-ganglionic  sympathetic 
neuron activity and it also enhances analgesia produced by Clonidine. This combination may 
be useful clinically23, 37. 
 
Sedation: 
 It commonly occurs after neuraxial administration of the Clonidine. After epidural 
administration, Clonidine by its systemic absorption and vascular redistribution to higher 
centers produces sedation38.  
Site of action:  
The brain stem nuclei called as locus ceruleus, which is involved regulation of sleep, 
wakefulness. It is inhibited by G Protein mediated mechanism that involves inhibition of 
adenyl cyclase.38 
 Dose Dependent Sedation:  
 Regardless of route of administration the Clonidine produces rapid sedation in less 
than 20 minutes over the dose range of 50-900 μg. After a large epidural bolus dose (700 
μg.) sedation is intense for 4 - 6 hours and reduced the need for other sedatives, anxiolytics 
when Clonidine given intraoperatively.40 
  
Unique feature of sedation: 
The Clonidine produces arousable sedation but with other drugs which acting on 
GABA receptor produces clouding of consciousness and causes paradoxical agitation. 
 
Respiratory depression:  
Although the respiratory depression produced by narcotics may be due to 
noradrenergic mechanism which is supported by some evidence. Clonidine alone do not 
induce respiratory depression even with massive doses41 and not potentiate the depression 
produced by narcotics42. Occasional reports of upper airway obstruction during deep 
sedation with Clonidine and which is accompanied by transient fall in oxygen saturation. So 
that monitoring the patients  with pulse-oxymetry may be needed for 30 minutes to 2 hours 
after large bolus doses. 
Hormonal effects:   
As it is a potent sympatholytic agent, it reduces but not suppresses the stress 
hormones like nor-adrenaline, adrenaline, ACTH, cortisol. 
It promotes the release of growth hormone45, but the effect is short lived.  This also reduces 
the insulin release by direct action on islet cells, but it is clinically 
 insignificant14 
Mechansim of antishivering effect:   
The clonidine synchronously decreases the cold-response threshold while slightly 
increasing the sweating threshold  and thus suggesting that it acts  on central thermal 
regulatory system rather than preventing shivering peripherally. 
Duration of Analgesia and Blood pressure effect of Epidural 
clonidine alone after surgery: 
The common side effects after epidural Clonidine are  
1. hypotension 
2. bradycardia  
3. drymouth 
4. sedation  
 
Epidural Clonidine produces dose dependent reduction in blood pressure and a 5 – 
20 % reduction in heart rate. In one study 181 patients received bolus epidural Clonidine 
after non obstetric surgery only 1% of patient received atropine for treatment of bradycardia 
and many patients received intravenous fluids for reduced blood pressure, none received 
intravenous vasoconstrictors. But in contrast none of 92 patients received epidural Clonidine 
by continuous infusion or PCA required atropine for bradycardia. But 8 patients (9%) 
received vasoconstrictors for hypotension. Sedation is common with bolus administration 
and lasts for 1 – 2 hours after 150 μg. and 2 - 4 hours after 400  μg.  But sedation is 
uncommon with continuous infusion.  But in all patients there is no evidence of respiratory 
depression by pulse oxymetry, PaCo2, ETCO2, or respiratory rate monitoring.  Epidural 
Clonidine, along with local anesthetics (150 μg. Clonidine + 9 ml. 0.25% Bupivacaine) during 
total hip replacement under general anesthesia, doubled the duration of post operative 
analgesia. When compared with Bupivacaine alone.54 
 
 Urinary retention and Clonidine: 
 Intrathecal opioids may produce urinary retention, but does not produce urinary 
retention but it may actually hastens the time to first micturition after spinal anesthesia65,67 
 
Blood and C.S.F pharmacokinetics of epidurally administered Clonidine: 
 In contrast to the blood, there is a strong correlation between the Clonidine 
concentration in C.S.F and analgesia after epidural administration, the concentration which 
produces EC95 (95% maxmimal effect) 130ng/ml and when this level is reached in the C.S.F. 
the P.C.A. approaches zero12, 13 
 
Parasympathetic system and Clonidine:  
 Clonidine produces bradycardia, AV nodal conduction delay may also occurs but not 
to the level to produce bradyarrythmias. Vasoconstriction, anti-shivering mechanism due to 
direct action on postsynaptic α2 receptors present in the vascular smooth muscle.  
 
Absorption: 
           It is well absorbed by all the routes - oral, intravenous, intramuscular, transdermal etc. 
The bioavailability is nearly 100% by oral route. Elimination half-life of 6 to 12 hours with the 
mean of 12 hours, about half the drug administered is excreted unchanged through urine 
and the half life of the drug is increased with renal failure. 
 
 
Metabolism: 
           The 50% of the drug is metabolized in the liver to inactive metabolites which are 
excreted in the urine. 
 
Drug interactions:   
           Tricyclic antidepressants and presumably phenothiazines and butyrophenones 
interfere with the action of Clonidine, but butyrophenone administration may produce 
hypertensive crisis at least theoretically, even though none has been reported. Acute 
Clonidine administration reduces anesthetic requirements by 40 to 60%.chronic 
administration reduces by 10 to 20%. 
 
Uses: 
1) as a pre-anesthetic medication 
2) helps to reduce the stress response  
3) helps to treat the withdrawal symptoms of  alcohol, narcotics, tobacco   
 as it reduces sympathetic manifestations  of withdrawal  
4) to treat the post menopausal hot flushes. 
5) to reduce the anesthetic requirement that is M.A.C. up to 95% 
6) helps to differentiate the pheochromocytoma and hypertension . 
7) helps to treat both intra-operative and postoperative shivering . 
8) improves the diarrhoea due to autonomic neuropathy. 
9) central neuraxial placement of clonidine alone or along with 
10) local anesthetics produces analgesia. 
11) To treat the postural hypotension as it has direct action on vascular            
smooth muscle 
 
 Side effects:  
1) excessive sedation in higher doses produces upper airway obstruction and decrease 
in oxygen saturation. 
2) dryness of the mouth 
3) contact dermatitis if it is used as a transdermal patch 
4) sexual dysfunction 
5) abrupt withdrawal  in hypertensive patients  leads to hypertensive crisis. 
 
 
 
 
 
  
 
 
Pharmacology of Bupivacaine 
Bupivacaine is an amide linked local anaesthetic. It is a hydrochloride salt of d (1) -1 - 
butyl 2,6 pipecoloxylidide and is presented as a racemic mixture. First report of its use was 
published in 1963 by Telivuo. It is derived from Mepivacaine and is very stable compound 
and may be autoclaved repeatedly. 
Pka - 8.1; MW - 288  
Protein binding - 95% 
Lipid solubility - 28 
Elimination half life - 210mts 
Toxic plasma concentration >1.5 (µg/ml) 
Approximate duration of action - 175mts  
Dosage - Maximum dosage 3mg/kg body weight. 
Uses: 
1. Spinal anaesthesia 
2. Epidural anaesthesia 
3. Caudal anaesthesia 
4. Continuous epidural anaesthesia 
5. Peripheral nerve block 
Pharmacokinetics:  
Once injected intrathecally, it gets absorbed by the nerve rootlets and results in the 
desired effect. It is rapidly absorbed from the site of injection, but the rate of absorption 
depends on the vascularity at the site and presence of vasoconstrictors.  
      High lipid solubility of Bupivacaine makes it easy for nerve and vascular tissue 
penetration. 80-95% of the absorbed Bupivacaine binds to the plasma. 
Distribution: 
Rapid distribution phase:  
      In this phase the drug is distributed to highly vascular region t1/2 being 2.7 minutes.      
Slow disappearance phase:  
      In this phase the drug distributes to slowly equilibrating tissues t1/2 being 28 mts.  
 Biotransformation and excretion phase: 
      T1/2 is 3.5hours  
       Clearance is 0.47 litres/minute.  
 
Biotransformation: 
      Possible pathways of metabolism of Bupivacaine include aromatic hydroxylation and 
conjugation. Only the N-dealkylated metabolite, N-desbutyl bupivacaine has been 
measured in blood (or) urine after epidural (or) spinal anaesthesia. Alpha1 acid 
glycoprotein is the most important plasma protein binding site of Bupivacaine and its 
concentration is increased by many clinical situation including post operative trauma.  
Excretion: is through the kidney, 4-10% of the drug is excreted unchanged.  
 
Mode of Action: 
a) Site of action: 
The spinal nerve rootlet fine nerve filaments having a large surface area are exposed to the 
local anaesthetics. Posterior and lateral aspects of the spinal cord itself.  
b) Sodium Channel blockade: 
      They impede sodium ion access to the axon interior by occluding the transmembrane 
sodium channels thus delaying the process of depolarization and axon remains polarized. 
It is a non-depolarization blockade.      
 
 
Pharmacodynamics: 
      It has got a longer duration of action but a slower onset.  
Cardio vascular system: 
      It reduces cardiac output by reducing the sympathetic tone, by slowing the heart rate 
and by reducing the venous return, it produces a fall in arterial blood pressure but it is 
relatively slow and is seldom very profound.  
      It produces a fall in central venous pressure. It causes an increase in lower limb blood 
flow. It causes a reduction in incidence of deep vein thrombosis.  
Respiratory System: 
      Spinal blockade seldom, if ever causes respiratory problem.  
Gastro intestinal tract: 
      There is an increase in gastro intestinal motility and emptying of the gastric contents is 
better.   
 Toxicity: 
      Toxicity is related to plasma level of unbound drug and more likely due to an 
inadvertent intravenous injection. Systemic toxicity reactions primarily involve central 
nervous system and cardio vascular system. The blood level required to produce central 
nervous system toxicity is less than that required to produce circulatory collapse.   
Central Nervous System Toxicity:    
      Initial symptom includes feeling of light headedness and dizziness, followed by visual 
and auditory disturbances. Objective signs are excitatory and include shivering, muscle 
twitching and tremor. Ultimately generalized tonic, clonic seizures occurs.  
Cardiovascular System Toxicity: 
      The rate of depolarization in fast conducting tissue of purkinje fibers and ventricular 
muscle is decreased. The rate of recovery of Bupivacaine induced block is slower than that 
of lignocaine. Extremely high concentration of the drug causes sinus bradycardia and 
cardiac arrest. 
 
 
 
 
 
 
 
 
 
Anatomy of the spinal cord 
        It is covered by three meninges, the outer most is dura and it extends from the skull 
where it fuses with foramen magnum The caudal tip is at the level of S2 segment. 
 Structure of the dura: 
Dura: is composed of collagenous lamellae and elastin elements separated by clefts filled 
with ground substance which account for permeability. 
Arachnoid and pia : Immediately within the dura is the arachnoid matter which encloses  
the subarachnoid space. 
      Subarachnoid block means the temporary interruption of nerve transmission within the 
subarachnoid space produced by injection of a local anaesthetic solution into cerebrospinal 
fluid. 
Applied anatomy of vertebral canal: 
      Vertebral canal extends from foramen magnum to the sacral hiatus. It protects the spinal 
cord. The vertebral column comprises of 33 vertebrae (7-cervical, 12-thoracic, 5-lumbar, 5-
fused sacral and 4-coccygeal) has four curves. Cervical and lumbar curves are convex 
anteriorly and thoracic & sacral curves are convex posteriorly. The curves of the vertebral 
column influence the spread of the local anaesthetic in the subarachnoid space.  
      Each vertebra is composed of a body separated from the adjacent vertebra by 
intervertebral disc and vertebral and formed by pedicles and laminae, which surround and 
protect the cord laterally and posteriorly.  
The vertebral column is bound together by several ligaments. They are, 
1. Supraspinal ligament passes longitudinally over the tips of the spinous processes 
from C7 to the sacrum. 
2. Interspinous ligament connects the adjoining spinous processes together.  
3. Ligamentum Flavum known as yellow ligament, connects the adjacent laminae 
composed of yellow elastic fibers. They become progressively thicker from above 
downwards. 
4. Posterior longitudinal ligament is on the posterior surface of bodies of vertebral. 
5. Anterior longitudinal ligament runs along the front of the vertebral bodies. 
There are seven projections from these vertebral (or) neural arches. They are 3 muscular 
processes, 2-Transverse processes and 1-spinous process for the attachment of muscle and 
ligaments. Four articular processes - 2 upper & 2 lower which, in the lumbar region, prevent 
rotation but allow limited flexion and extension between contiguous vertebrae. 
Vertebral canal formed by these structures has deficiencies posteriorly in the midline called 
inter laminar foramina which enlarge in flexion accessible for the passage of spinal needle. 
The direction of spinous process determines the direction of spinal needle.  
 
SPINAL CORD 
      It is the direct continuation of the medulla oblongata extending from the upper border of 
the atlas to the first lumber vertebra below which there is leash of nerve roots termed cauda 
equina. Spinal nerves are 31 pairs totally - 8 Cervical, 12 Thoracic, 5 Lumbar, 5 Sacral, 1   
Coccygeal          
      Each of the spinal nerve is composed of anterior and posterior roots uniting at the inter 
vertebral foramina and form a nerve trunk. Membranes covering the spinal cord from without 
are dura mater, arachnoid mater and piamater. Dura and arachnoid mater end at S2 level. 
Piamater is closely applied to the spinal cord.  
BLOOD SUPPLY: It is from the anterior spinal artery which is a branch of vertebral artery 
and also by a pair of posterior spinal arteries which arise from the posterior inferior 
cerebellar arteries. There is no anastamosis between these arteries. 
VENOUS DRAINAGE: The spinal veins are arranged into anterior and posterior plexus 
which are draining into vertebral, azygos and lumbar veins.         
CEREBROSPINAL FLUID 
      This is an ultra-filtrate of the blood plasma from choroids plexus of the lateral ventricles 
with a pH of 7.32 (7.27-7.37). It is a clear, colourless fluid found in the cranial and spinal 
subarachnoid spaces and in the ventricle of the brain. The total volume of CSF in an 
average adult ranges from 120-150ml of which 25-35ml is in the spinal subarachnoid space. 
Composition of cerebrospinal fluid: 
Specific gravity - 1.006 (1.003-1.009) at 370C  
Pressure - 60-80mm of H2O 
PCO2 - 48mmHg 
HCO3 - 23meq/l 
Na+    - 133-145meq/l 
Ca+    - 2-3meq/l 
Po4-    - 1.6meq/dl 
Mg+    - 2-2.5meq/l 
Cl-    - 15-20meq/l 
Protein   - 23-38mg/dl 
Sugar    - 45-80mg/dl 
Lymphocytes - 0-5cells/cmm 
      An important factor that determines the spread of drug in cerebrospinal fluid is the 
specific gravity of the drug in relation to that of cerebrospinal fluid (Baricity) which is 1.003-
1.009. Hyper baric solution is one which is denser than CSF at 370C.   
 
 PHYSIOLOGY OF SUBARACHNOID BLOCK: 
      Subarachnoid block implies the temporary interruption of nerve transmission within the 
subarachnoid space by injections of local anaesthetics. The blockade of nerve fibres occur in 
the order of Temperature, Pain, proprioceptive and then motor fibres.   
FACTORS INFLUENCING BLOCK HEIGHT: 
a - Site of injection  
b - Angulation of needle  
c - Characteristic of local anaesthetic 
i) Density of local anaesthetic  
ii) Specific gravity 
iii) Baricity 
d - Dose of local anaesthetic 
e - Position of the patient during and after injection 
f - Anatomic configuration of spinal column. 
g - Patient height (at extremes) 
h - Reduced cerebrospinal fluid with increased intra abdominal pressure (eg. Pregnancy)  
a) Effects on Cardio Vascular System:    
      Most important physiological responses to subarachnoid block involve cardio vascular 
system due to combined effect of autonomic denervation, higher level of neural block, added 
effect of vagal innervation. Local anaesthetics and vasoactive substances administered in 
small doses intrathercally leads to direct cardiovascular effect. Level of sympathetic 
denervation determines the magnitude of cardio vascular system responses, but the 
relationship is neither predictable nor precise.  
      Sympathetic denervation produces arterial and more physiologically important arteriolar 
dilatation and vasodilatation in the venous circulation produces fall in blood pressure. Due to 
loss of Bainbridge reflex, the fall in blood pressure is associated with bradycardia, blockade 
of cardiac sympathetic fibres from T1-T4 is an additional factor that causes bradycardia. 
b) Effects on Respiratory System: 
      Respiration is not depressed normally. High spinal can cause paralysis of intercostals 
muscles but resting tidal volume, maximum inspiratory volume, respiratory rate, ABG, 
negative intrapleural pressure and also the phrenic nerve are unaffected. Hypoxia may 
accompany hypotension and is corrected by oxygen administration via face mask.  
c) Gastro Intestinal Effect:  
Pre-ganglionic fibres from T5-L1 are inhibitory to gut. So in sympathetic blockade the 
small intestine contracts with relaxed sphincters and peristalsis remains normal. Handling of 
viscera causes discomfort and bradycardia since vagus is not blocked.  
d) Hepatic and Renal Effects: 
      The hepatic blood flow decreases and is directly proportional to the decrease in blood 
pressure. There may be normal hepatic oxygen extraction. Renal blood flow is maintained by 
autoregulation and does not decrease till mean arterial pressure goes below 50mmHg.  
      Sphincters of bladder are not relaxed, and tone of ureters is not greatly altered. Urinary 
retention occurs. Penis is often engorged, and erigentes (S2, S3). Uterine tone is unchanged 
in pregnancy. In the absence of hypotension spinal anaesthesia has got no effect on the 
progress of labour and uterine blood flow.   
f) Metabolic and hormonal effect: 
      Spinal anaesthesia blocks hormonal and metabolic responses to nociceptive stimuli 
arising from the operative site. It minimizes the rise in blood sugar, coritsol, catecholamines 
renin and aldosterone release associated with stress. Post operative negative nitrogen 
balance and secretion of anti-diuretic hormone are inhibited.   
g) Thermo Regulation: 
      Hypothermia results from heat loss to the cold environment due to vasodilatation. 
 
 
 
AIM OF THE STUDY 
 
 
1. To evaluate the efficacy of Clonidine in prolonging the duration of post operative analgesia 
when combined with Bupivacaine. 
2. To study the property of Clonidine to potentiate the analgesic effect of Bupivacaine. 
3. To observe the safety of intrathecally administered Clonidine. 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
 
Bonnet et al 15, 26, 48, 60, 62 studied spinal Clonidine as adjuvant with Bupivacaine in orthopedic 
surgeries and proved that the combination was effective in preventing the tourniquet pain 
and effectively prolonging the post-op analgesia.  
 
Fogarty et al63 compared spinal Clonidine vs morphine with Bupivacaine in 
patients undergoing total hip replacement surgeries. Intrathecal Clonidine prolonged the 
duration of spinal analgesia, but was markedly inferior to the intrathecal morphine in 
providing subsequent postoperative analgesia  
 
Grace et al3 studied the co administration of Pethidine with Clonidine in spinal anaesthesia 
for total hip replacement surgeries.  
 
Monica brunschwiller et al compared intraoperative anaesthetic and   
haemodynamic effects of clonidine-bupivacaine, morphine-bupivacaine   
and placebo-bupivacaine combinations during continuous spinal anaesthesia in knee 
replacement surgeries and concluded that 0.15 mg Clonidine but not 0.15 mg morphine 
prolonged surgical analgesia when added to 10 mg plain Bupivacaine.   
 
Pan et al studied the analgesic effects of intrathecal neostigmine vs  
Clonidine with Bupivacaine in cesarean section. Their study showed that the  
combination of 150 µg Clonidine and 50 µg neostigmine provided longer  
post-surgical analgesia than with either drug used alone. However, this combination also 
produced significantly more adverse effects of prolonged motor block and nausea, vomiting.  
 Philip .j.siddall et al studied that the efficacy of Intrathecal Morphine and   
Clonidine in the treatment of pain after spinal cord Injury. They Demonstrated that 
administration of a combination of morphine and Clonidine into the spinal fluid can provide 
substantial pain relief in some people with this type of pain.  
 
Dekock.m.et al 17,34,36,39,53 studied spinal clonidine with ropivacaine in ambulatory knee 
arthroscopy surgeries. They concluded that Small-dose intrathecal clonidine (15 µg) plus 8 
mg intrathecal ropivacaine produces adequate and short-lasting anesthesia for knee 
arthroscopy.  
 
Debrydnjov I et al 75 have tried 6 mg of 0.5% heavy Bupivacaine with 15µg vs 30µg of 
Clonidine for unilateral spinal anaesthesia in unilateral inguinal hernia surgeries and showed 
it have produced excellent post-op analgesia. They concluded that use of 
Clonidine as adjuvant to small dose 6mg Bupivacaine for ambulatory inguinal herniorraphy.  
 
Michael j. peach et al (10.(2004) anaes analg., 2004;98;56-59) studied intrathecal fentanyl 
with morphine and varying doses of Clonidine in cesarean surgeries for post-op analgesia. A 
multimodal approach to post-cesarean analgesia, using subarachnoid Bupivacaine, fentanyl, 
morphine 100µg, and Clonidine 60µg, improves pain relief compared with morphine 100µg 
or clonidine 150µg alone, but increases intra-operative sedation and may increase peri-
operative vomiting.  
 
 Alain rochette et al  studied  spinal Clonidine in neonates. Spinal anesthesia is suitable but 
often too short for complete surgery in newborns. This controlled, randomized, prospective, 
dose-ranging study was conducted in 75 neonates to test the hypothesis that Clonidine 
could significantly lengthen Bupivacaine spinal block. He concluded  
that Clonidine 1µg/kg, added to spinal isobaric Bupivacaine, doubles the duration of the 
block without significant deleterious hemodynamic or respiratory side effects.  
 
Van tuiji et al (12. (2006) br. J. an. 97(3); 365-70) have studied the addition of intrathecal 
clonidine to hyperbaric Bupivacaine on post-op pain and morphine requirements after 
cesarean section. They concluded that addition of 75µg Clonidine to hyperbaric Bupivacaine 
2.2 ml prolongs spinal analgesia and motor block after cesarean section and improves early 
analgesia without any clinically relevant maternal or neonatal side effects.  
 
B.s.sethi et al (13.(2007) I.J.A) have studied the efficacy of low dose intrathecal Clonidine 
as adjuvant to bupivacaine in gynaecological surgeries. They have added 1µg/kg of 
Clonidine with 2.5 ml of Bupivacaine vs plain Bupivacaine. .They concluded that by adding 
Clonidine, the post op analgesia is significantly prolonged with an effect on sedation, heart 
rate and MAP which does not require any therapeutic intervention.  
MATERIALS AND METHODS 
 
Study design: 
This study was a randomized prospective comparative study. 
 
Study setting and population: 
After obtaining institutional ethical committee clearance, the study was carried out on 70 
patients in the OT, Department of Anesthesiology, Tirunelveli Medical College, Tirunelveli, 
from April to August 2009. 
 
Inclusion criteria:- 
         Pregnant patients belonging to ASA I and II were randomly selected between 18 to 28 
years of age, and weighing between 45-70 kgs.  
Exclusion criteria: 
1. Patients with systemic illness like diabetes, hypertension 
2. Asthmatic, COPD 
3. PIH, Patients on anti-hypertensives,  
4. Patients with partial block or failed block 
5. Height less than 145 cm 
6. Procedures ending with hysterectomy or requiring blood transfusion 
7. Anemia, bleeding disorders 
8. Contraindication to Clonidine 
9. Patients with psychiatric problems  
10. Patients having spinal deformities 
      
PRE OPERATIVE EVALUATION:- 
 In all the patients, Age, I.P.No, Body Weight, Baseline vital parameters were 
recorded. History regarding previous anaesthesia, surgery, any significant medical illness, 
medications and allergy were recorded. Complete physical examination and Airway 
assessment were done.  
 Following laboratory investigations were done: 
 Hemoglobin % 
 Blood : sugar, urea, S. Creatinine 
 S. Electrolytes : Na+, K+ 
 ECG in all leads 
 
STUDY METHOD: 
 
 After getting, informed consent, the patients were randomly allocated into two 
groups.  Group ‘B’ (n = 35) was taken as Bupivacaine group and Group ‘C’ (n = 35) as 
Clonidine group.  The 10 point visual analogue pain scale VAPS was explained to the 
patients. 
All the patients were premedicated with Inj. metoclopramide 10mg i.v, and Inj. 
ranitidine 50mg i.v 1 hour prior to anaesthesia. Standard monitoring was instituted after 
shifting the patient on the operating table. Baseline measurements of pulse rate, blood 
pressure and SpO2 were recorded. 
An intravenous access was established and the patients were pre-loaded with ringer 
lactate 10ml/ kg.  They were then positioned in the right lateral position on a horizontal table.  
After strict aseptic precautions, the L3-L4 inter space was identified and a 23 gauge spinal 
needle was used for sub-arachnoid placement. 0.5% hyperbaric bupivacaine 10 mg was 
injected in B group and 0.5% hyperbaric bupivacaine 10 mg + clonidine 75µg was injected in 
C group. The patients were then turned supine and a wedge placed under the right buttock. 
The level of sensory blockade was assessed by pin prick and the surgery proceeded after 
adequate motor and sensory block were achieved. The pulse rate and blood pressure were 
monitored at an interval of every 2 min till the delivery of the baby and every 5 minutes 
thereafter.  A fall of MAP by 25% from the base line value was considered as hypotension 
and managed with intravenous fluids, oxygen and Inj. ephedrine in titrated incremental 
doses. 
 Post-operatively the patients were instructed to mark a point on the 10 point visual 
analogue pain scale according to the intensity of pain.  The pain relief was graded as follows 
in VAPS. 
 
 
Pain Score Quality of analgesia 
0 -1 Excellent 
2 – 4 Good 
5 – 6 Fair 
7 – 8 Poor 
9 – 10 No relief 
 
 The pain score was assessed every hour and the total duration of post operative 
analgesia was taken as the period from the time of injection of the spinal anesthetic till the 
first requirement of systemic analgesic medication. 
In both groups patients were given the first analgesic medication when the VAPS score was 
6 and above.  Patients were observed for any side effects like respiratory depression, 
nausea, vomiting, urinary retention, hypotension, bradycardia for 24 hours. 
 
 
 
 
 
 
 
 
 
 
 OBSERVATION AND RESULTS 
  
The study was conducted on 70 patients randomly allotted into 2 groups as given below and 
the VAPS assessed:- 
 
VAP SCORE (2nd HOUR) 
GROUP ‘B’ GROUP ‘C’  
PAIN SCORE 
No.of 
patients 
% No.of 
patients 
% 
0-1 35 100 35 100 
2-4 0 0 0 0 
5-6 0 0 0 0 
> 7 0 0 0 0 
 
After 2 hours post-operatively, both B and C group patients exhibited a pain score of 0 – 1 
and were comfortable, manifesting no signs of pain. 
 VAP SCORE (3rd HOUR) 
GROUP ‘B’ GROUP ‘C’  
PAIN SCORE No.of 
patients 
% No.of 
patients 
% 
0-1 7 20 21 60 
2-4 20 57 9 26 
5-6 6 17 5 14 
> 7 2 6 0 0 
 
 
After 3 hrs, 8 patients in group B manifested mild to moderate levels of pain requiring 
systemic analgesic supplementation. 
In group C only 5 patients manifested pain which required analgesic supplementation. 
  
 
VAP SCORE (4th HOUR) 
GROUP ‘B’ GROUP ‘C’  
PAIN SCORE 
No.of 
patients 
% No.of 
patients 
% 
0-1 3 8 20 57 
2-4 1 3 7 20 
5-6 6 17 6 17 
> 7 25 72 2 6 
 
 
After 4 hrs, 31 patients in group B manifested pain requiring systemic analgesic 
supplementation. 
In group C only 8 patients manifested pain which required analgesic supplementation. 
 
 
 
 
VAP SCORE (6th HOUR) 
GROUP ‘B’ GROUP ‘C’  
PAIN SCORE 
No.of 
patients 
% No.of 
patients 
% 
0-1 0 0 6 17 
2-4 1 3 6 17 
5-6 4 12 10 30 
> 7 30 85 13 36 
 
After 6 hrs, 34 patients in group B manifested pain, with almost 97% requiring systemic 
analgesic supplementation.  
In group C only 23 patients manifested pain, with an average only 66% required analgesic 
supplementation. 12 of the patients did not show any sign of pain, which is 34% of the study 
group had good analgesic effect even after 6 hrs duration. 
 
STATISTICAL ANALYSIS 
 
 The clinical trial clients had been matched for comparison in respect of their 
age and body weight by computing mean and SD. The significance of the mean ages was 
interpreted by UNPAIRED‘t’ test. Duration of pain relief, two segment regression and the 
hemodynamics like MAP, PR, SPO2 were measured at different time periods and compared 
between the ‘B’ and ‘C’ group by mean and SD and interpreted by students unpaired ‘t’ test. 
 The above statistical procedures were undertaken by SPSS (130) at 5% 
level of significance (P = 0.05). The clients were matched in respect of their age and weights 
for comparison of the effect of two drugs (B and B+C) since the two variables were termed 
as independent variables and which were responsible for the pain relief. 
 
 
 
 
 
 
 
 
 
 
MATCHING OF THE TWO GROUP BY THEIR AGE 
AGE GROUP Group B Group C 
BUPIVACAINE CLONIDINE YRS 
No % No % 
20 – 24 21 60 23 65.7 
25 – 29 14 40 12 34.3 
TOTAL 35 100 35 100 
MEAN 23.4 23.3 
SD 1.9 1.9 
‘t’ 0.369 
Significance P > 0.05 
 
 The mean ages between the two groups were 23.4 ± 1.9 and 23.3 ± 1.9 for B and C group 
respectively. The difference between two mean ages was not statistically significant (P > 
.05). 
 Matching of the B and C group with reference to their body weight 
Group B 
BUPIVACAINE 
Group C 
CLONIDINE 
WEIGHT  
KGs 
No % No % 
50 – 55 2 5.7 3 8.6 
55 – 60 6 17.2 13 37.1 
60 – 65 23 65.7 18 51.4 
65 - 70 4 11.4 1 2.9 
TOTAL 35 100 35 100 
MEAN 61.1 59.7 
SD 3.2 3.5 
‘t’ 1.734 
Significance P > 0.05 
 
The mean weights between the two groups were 61.1 ± 3.2 and 59.7 ± 3.5 for B and C 
group respectively. The difference between two mean weights was not statistically significant 
(P > 0.05). 
 
 The two groups were matched with reference to their age and weight and 
they were amenable for comparison of other variables like duration of analgesia, 2 segment 
regression, MAP, PR, SPO2. 
 
Comparison of duration of analgesia 
B group C group CATEGORY N 
Mean SD Mean SD 
Mean 
Difference
‘t’ Diff significance 
Duration of 
analgesia 
35 176.9 69.5 288.6 130.3 111.7 4.475 68 P < 0.01 
Time to 2 
segment 
regression 
35 126.8 56.5 214.6 103.5 87.8 3.955 68 P < 0.01 
 
The mean “duration of analgesia” and mean “Time to 2 segment regression” between the 
two groups were statistically significant (P < 0.01). 
 
Comparison of hemodynamic variables between the two groups 
B group C group Time 
Mins. 
MEASURES n 
Mean SD Mean SD 
Mean 
Difference
‘t’ Diff significance 
MAP 35 83.4 6.4 82.5 4.5 0.9 0.669 68 P > 0.05 5 
PR 35 88.2 8.1 87.8 7.2 0.4 0.234 68 P > 0.05 
 SPO2 35 99.4 0.6 99.9 0.4 0.5 4.407 68 P < 0.01 
MAP 35 86 5.5 84 5 2 1.604 68 P > 0.05 
PR 35 88.9 6.9 88.6 7.4 0.7 0.548 68 P > 0.05 
10 
SPO2 35 99.4 0.7 97.7 1.7 51.7 5.376 68 P < 0.01 
MAP 35 86.6 5.3 84.9 4.7 1.7 1.425 68 P > 0.05 
PR 35 88 6.3 88.3 8.1 0.3 0.148 68 P > 0.05 
15 
SPO2 35 99.5 0.5 96.8 1.4 2.7 10.791 68 P < 0.01 
MAP 35 86.5 5.4 84.5 4.2 2 1.687 68 P > 0.05 
PR 35 86.8 6.4 88.8 8 2 1.17 68 P > 0.05 
20 
SPO2 35 99.4 0.6 97.1 1.4 2.3 8.963 68 P < 0.01 
MAP 35 87.4 5.8 86 4.4 1.4 1.14 68 P > 0.05 
PR 35 87 6.5 87.7 6.9 0.7 0.393 68 P > 0.05 
30 
SPO2 35 99.5 0.6 96.9 1.3 2.6 10.882 68 P > 0.01 
MAP 35 88.8 7 87 7.2 1.8 1.054 68 P > 0.05 
PR 35 83.7 8.7 83.2 8.2 0.5 0.239 68 P > 0.05 
60 
SPO2 35 99.5 0.6 98 1.2 1.5 6.948 68 P > 0.05 
MAP 35 89.2 6.9 86.8 7.7 2.4 1.351 68 P > 0.05 
PR 35 83.1 8.6 83.6 9.6 0.5 0.223 68 P > 0.05 
90 
SPO2 35 99.5 0.5 98.8 1.1 0.7 3.66 68 P < 0.01 
120 MAP 35 87.9 6.5 87.4 7.8 0.5 0.283 68 P > 0.05 
PR 35 83.2 8.8 83.9 9 0.7 0.349 68 P > 0.05  
SPO2 35 99.6 0.5 98.5 1.3 1.1 4.514 68 P < 0.05 
 
 
 
 The hemodynamic variables such as MAP, PR did not significantly differ at 
all the time periods of monitoring (5, 10, 15, 20, 30, 60, 90,120). 
 
 The SPO2 of B group was lesser than C group at 5th minute only. In all other 
time periods, the SPO2 of the C group was lesser than B group which is statistically 
significant, though it is not clinically significant. 
 
 
 
  
 
 
 
 
DISCUSSION 
  
 Clonidine added to Bupivacaine for spinal anaesthesia in Caesarean section 
improves the analgesia in the immediate postoperative period. The effective dose range of 
intrathecal Clonidine for post-op analgesia is not known to date. Actually all effects of 
Clonidine including analgesia are dose dependent. The present study suggests that 
compared to Bupivacaine alone, the addition of 75 µg Clonidine to Bupivacaine produced a 
strong analgesia with a mean duration of 288 mins. Furthermore our patients were not 
administered any additional opioids or tranquilizers peri-operatively that may have 
potentiated the analgesic action of Clonidine. 
  
Coombs et al suggested the combination of intrathecal Clonidine 150µg and morphine 
produced analgesia for 8 hrs. 
 
Van Tuiji et al studied the effect of addition of intrathecal Clonidine to hyperbaric 
Bupivacaine on postoperative pain and morphine requirements after Caesarean section. He 
demonstrated that addition of 75 µg Clonidine to 
hyperbaric Bupivacaine prolongs spinal analgesia and the motor block after caesarean 
section and improves early analgesia. 
 In the present study using Clonidine 75µg alone the analgesia lasted for a mean of 288 
mins. The dose is lesser than that used by Coombs et al, but the duration of analgesia is 
closer to that study even without opioid. 
Mondez et al 13used epidural Clonidine in doses of 400 and 800µg for caesarean section 
and they found that 800µg group had 5 hours of median duration of analgesia and this is 
closer to this present study. 
The present study shows that the intrathecal route required lesser dose than epidural route 
but with same duration of analgesia and is safer with no side effects.  
 
Kriton S.Filos et al 73 150,300,450 µg intrathecal Clonidine for its haemodynamic effects. 
They found the 300 and 450 µg group had haemodynamic stability, but the 150µg group 
presented with immediate fall in MAP but with no delayed fall in this group. There was no 
incidence of significant bradycardia in all the three groups. 
The present study with 75µg Clonidine also showed no significant haemodynamic changes. 
Moreover it had no measurable deleterious side-effects in mother. Although MAP was lower 
in the C group, this apparently was not considered clinically important, as the fall in MAP 
was manageable with I.V. fluids and the occurrence of bradycardia was not significantly 
different between the two groups. Furthermore, the average MAP did not decrease > 25% 
from baseline. 
 
 
 
 
 
 
SUMMARY 
 
The addition of 75 µg Clonidine to Bupivacaine produced a strong analgesia with a 
mean duration of  288 minutes (4 – 6 hrs). This extended analgesia offered by the studied 
dose was clinically and statistically significant, at the same time providing hemodynamic 
stability. The arousable sedation offered by the intrathecal administration of clonidine was 
also beneficial, requiring less and infrequent supplementation of systemic analgesics. 
Moreover, the side effects observed were no greater than that of administration of 
bupivacaine alone. In fact respiratory depression, urinary retention or pruritus were not even 
noted in any case, which otherwise would have been an embarrassing side effect of 
intrathecal opioid. 
  
 
 
 
 
 
 
 
CONCLUSION 
 
The present study has demonstrated that addition of 75 µg Clonidine to hyperbaric 
Bupivacaine prolongs post op analgesia and the two segment regression after Caesarean 
section, without clinically significant haemodynamic derangements or any adverse effects. 
Hence intrathecal clonidine along with bupivacaine proves to be a safer alternative to 
intrathecal opioids and with a dose of 75 µg, the hemodynamic profile is also very 
acceptable. Thus intrathecal clonidine 75 µg not only potentiates and prolongs the analgesic 
effect of bupivacaine, but also has a good safety profile for intrathecal use. From this study it 
could be concluded that addition of 75µg of Clonidine to hyperbaric Bupivacaine is safe and 
beneficial to pregnant patients posted for LSCS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MASTER CHART: GROUP C – CLONIDINE 
 
VAPS INITIAL 
BLOCK 
2 SEG 
REG 
COS.N
o 
NAME AGE WT DUR
ATIO
N 
2nd hr 3rd hr 4th hr 6th hr   Na
Vo
1 Shanbag
am 
22 50 135 1 5 X X T5 90 NIL
2 Sundari 21 52 317 0 1 4 5 T4 240 NIL
3 Anaantha
valli 
20 58 199 0 4 X X T4 140 NIL
4 Anathalak
hsmi 
23 62 147 1 5 X X T45 11O NIL
5 Kavitha 25 64 220 0 4 6 X T4 150 NIL
6 Saraswath
i 
26 65 245 0 4 6 X T4 160 NIL
7 Geetha 25 62 315 0 1 4 6 T4 240 Nil 
8 Keetha 24 62 240 0 2 5 X T4 175 Nil 
9 Selvi 23 60 160 0 4 5 X T4 120 NIL
10 Subbulaks
hmi 
22 59 285 0 2 4 5 T4 210 Nil 
11 Maharasi 21 57 275 0 2 4 5 T4 200 Nil 
12 Sorna 20 58 240 1 4 6 X T4 190 Nil 
13 Vijayalaks
hmi 
21 59 199 1 4 6 X T4 150 Nil 
14 Indira 22 62 421 0 0 2 4 T4 340 Nil 
15 Subusfathi
ma 
23 64 260 0 2 4 6 T4 200 Nil 
16 Petchiam
mal 
25 61 280 0 2 4 5 T4 205 Nil 
17 Lakshmi 26 62 290 1 4 6 X T4 210 Nil 
18 Revathi 26 59 222 0 4 6 X T4 15 N[l
19 Kalanjium 25 57 293 0 2 4 7 T4 210 Nil 
20 Grace 22 58 422 0 0 2 4 T4 320 Nil 
21 Muthupar
vathi 
26 55 392 0 0 2 5 T4 290 Nil 
22 Ananthar
ubi 
25 52 340 0 0 4 5 T4 260 Nil 
23 Parvin 24 58 220 0 2 6 X T4 170 Nil 
24 Priya 22 58 210 0 4 6 X T4 160 Nil 
25 Banjana 24 60 155 2 5 X X T5 100 Nil 
26 Noorali 26 62 210 0 4 6 X T4 160 Nil 
27 Barvani 22 63 720 0 0 0 2 T4 600 NIL
28 Shunmug
apriya 
21 64 280 0 1 `4 6 T4 200 Nil 
29 Subbulaks
hmi 
21 64 280 0 1 4 6 T4 200 NIL
30 Amuthaku
mari 
22 60 460 0 0 2 4 T4 330 Nil 
31 Fathima 21 61 280 0 2 4 6 T4 210 Nil 
32 Nanada 23 62 255 1 4 5 X T4 180 NIL
33 Sudha 25 61 255 0 2 4 6 T4 175 Nil 
34 Valli 26 59 180 2 4 7 X T5 110 Nil 
35 Sumathi 24 58 700 0 0 0 1 T4 490 Nil 
            
 
 
  
 
 
 
 
 
 
 
 
 
 
CLONIDINE HEMODYNAMIC PROFILE 
 
 
S.no NAME AGE MAP PULSE RATE 
   5 10 15 20 30 45 60 90 120 5 10 15 20 30 4
1 Shenbagam 22 73 72 74 78 80 70 68 68 68 96 90 84 86 85 9
2 Sundari 21 88 83 86 82 86 94 94 88 99 92 93 96 98 97 8
3 Anaanthavalli 20 76 78 80 83 82 82 83 87 87 68 69 74 88 86 7
4 Anathalakhsmi 23 80 83 87 87 90 96 97 96 98 91 94 102 104 100 9
5 Kavitha 25 83 79 92 89 92 80 78 76 76 88 89 90 86 92 8
6 Saraswathi 26 87 86 86 89 88 85 86 87 84 90 92 90 96 86 7
7 Geetha 25 81 87 85 82 83 93 95 96 95 92 94 96 92 91 8
8 Keetha 24 93 95 92 88 92 97 93 91 96 92 93 94 95 96 8
9 Selvi 23 84 83 82 81 86 86 90 87 90 91 92 93 86 84 8
10 Subbulakshmi 22 80 83 86 83 81 82 86 92 83 91 92 90 84 84 8
11 Maharasi 21 81 86 85 83 85 91 96 96 98 98 99 100 97 91\ 9
12 Sorna 20 80 85 83 81 82 83 85 82 86 92 86 80 80 80 8
13 Vijayalakshmi 21 85 89 84 92 90 84 84 85 86 90 88 84 86 86 7
14 Indira 22 81 83 83 82 83 78 76 80 82 90 91 87 86 84 8
15 Subusfathima 23 83 81 85 86 84 93 90 86 88 82 80 83 84 86 8
16 Petchiammal 25 80 81 90 86 83 78 78 77 81 88 87 90 91 85 8
17 Lakshmi 26 82 85 92 86 93 96 95 99 94 83 86 87 92 98 9
18 Revathi 26 83 81 80 82 83 86 86 90 88 78 76 79 89 84 7
19 Kalanjium 25 76 80 83 82 92 93 91 94 95 100 102 106 110 100 9
20 Grace 22 93 94 92 90 91 98 97 95 98 86 84 85 83 87 8
21 Muthuparvathi 26 80 79 81 79 83 83 84 81 80 89 90 87 86 90 8
22 Anantharubi 25 76 78 79 82 82 80 78 81 83 76 78 80 81 80 7
23 Parvin 24 85 92 91 93 92 93 92 93 96 91 90 89 87 89 8
24 Priya 22 80 85 81 82 83 78 76 75 80 78 74 70 68 68 7
25 Banjana 24 85 94 90 92 94 95 94 96 91 80 84 86 87 90 9
26 Noorali 26 86 83 86 85 90 93 98 98 98 92 94 95 94 92 9
27 Barvani 22 80 82 82 83 83 80 82 83 85 74 76 77 72 75 6
28 Shunmugapriya 21 83 86 88 90 90 93 89 83 83 87 86 84 88 87 8
29 Subbulakshmi 21 80 83 80 78 78 78 82 78 79 86 84 82 86 82 8
30 Amuthakumari 22 80 80 82 79 84 83 85 90 93 94 96 94 92 87 8
31 Fathima 21 81 80 83 81 82 82 88 80 82 90 84 86 85 86 7
32 Nanada 23 84 87 93 90 89 93 89 92 94 92 94 95 94 96 8
33 Sudha 25 83 84 80 83 83 78 83 86 77 78 82 80 84 80 7
34 Valli 26 93 92 90 87 90 92 95 92 89 91 92 94 93 90 8
35 Sumathi 24 83 82 79 83 82 80 81 79 78 96 98 100 100 95 9
 
 
 
 
MASTER CHART : GROUP B – BUPIVACAINE 
 
 
 
VAPS INITIAL 
BLOCK 
2 
SEG 
REG 
COMPLICATIONS S.No NAME AGE WT DURATION 
2nd 
hr 
3rd 
hr 
4th 
hr 
6th 
hr 
  Nausea 
Vomiting 
Urinary 
retention
1 Syed Ali 20 52 85 6 X X X T6 65 NIL NIL 
2 Muthulakshmi 22 53 100 5 X X X T6 70 NIL NIL  
3 Rajeshwari 24 61 145 5 X X X T5 100   
4 Sheik Fatima 25 64 133 5 X X X T5 100 NIL NIL 
5 Muthusundari 22 65 140 5 X X X T5 115 NIL NIL 
6 Anis Fatima 26 62 325 0 2 5 X T4 240 NIL NIL 
7 Subbuthai 23 58 215 0 2 5 X T4 160 NIL NIL 
8 Saradha 21 56 147 5 X X X T5 95 NIL NIL 
9 Andal 25 58 155 5 X X X T5 100 NIL NIL 
10 Shanthi 24 61 121 5 X X X T5 75 NIL NIL 
11 Pechiammal 25 63 165 2 5 X X T4 120 NIL NIL 
12 Mahalakshmi 26 65 172 0 2 5 X T4 125 NIL NIL 
13 Syed ali 21 56 160 1 4 6 X T4 120 NIL NIL 
Fatima 
14 Mari 22 64 228 0 2 5 X T4 165 NIL NIL 
15 Saraswathi 23 62 175 0 2 6 X T4 125 NIL NIL 
16 Gomathi 21 61 163 0 6 X X T4 120 NIL NIL 
17 Priya 25 60 218 0 2 6 X T4 155 NIL NIL 
18 Ayisha 
begam 
26 59 92 5 X X X T6 55 NIL NIL 
19 Roobini 25 62 160 2 6 X X T5 110 NIL NIL 
20 Selvi 26 63 60 7 X X X T6 40 NIL NIL 
21 Mariammal 22 64 120 4 7 X X T5 75 NIL NIL 
22 Sudali 23 65 120 5 X X X T6 70 NIL NIL 
23 Usha rani 20 65 144 0 5 7 X T5 95 NIL NIL 
24 Uma 22 62 150 0 4 6 X T5 100 NIL NIL 
25 Asha 21 61 360 0 2 4 6 T4 260 NIL NIL 
26 Dhanam 24 62 200 0 4 7 X T4 155 NIL NIL 
27 Muthulakshmi 24 63 140 1 6 X X T5 85 NIL NIL 
28 Saraswathi 25 60 215 1 4 6 X T4 150 NIL NIL 
29 Sophia 26 58 240 0 3 5 X T4 180 NIL NIL 
30 Prema 21 62 280 0 1 4 6 T4 220 NIL NIL 
31 Banu 22 63 165 2 6 X X T6 110 NIL NIL 
32 Amudharani 25 64 350 0 1 4 5 T4 285 NIL NIL 
33 Maharasi 25 61 170 0 4 7 X T6 115 NIL NIL 
34 Rabia 26 60 215 0 3 6 X T4 150 NIL NIL 
35 Krithika 22 62 165 1 5 7 X T5 115 NIL NIL 
 
 
 
  
 
 
 
 
 
 
 
BUPIVACAINE HEMODYNAMIC PROFILE 
 
 
AGE MAP PULSE RATES.no NAME 
 5 10 15 20 30 45 60 90 120 5 10 15 20 30 
1 Syed Ali 20 66 72 72 70 78 82 81 91 87 78 86 84 85 91 
2 Muthulakshmi 22 80 86 84 85 90 90 88 94 96 92 90 87 86 84 
3 Rajeshwari 24 85 84 91 86 93 99 97 98 100 96 94 90 90 88 
4 Sheik Fatima 25 90 90 91 90 96 96 98 96 86 92 90 91 88 92 
5 Muthusundari 22 82 83 84 87 91 93 96 96 93 98 100 101 97 98 
6 Anis Fatima 26 99 93 93 95 94 98 99 96 96 98 92 88 84 84 
7 Subbuthai 23 87 86 92 89 92 85 86 87 80 84 86 87 84 80 
8 Saradha 21 82 83 81 84 83 92 88 83 82 94 96 92 90 86 
9 Andal 25 80 82 80 81 88 91 96 94 94 100 98 94 96 92 
10 Shanthi 24 84 88 93 90 82 78 79 80 79 79 82 84 80 82 
11 Pechiammal 25 80 85 83 84 84 93 95 84 82 90 91 92 90 86 
12 Mahalakshmi 26 80 84 80 86 88 91 94 98 95 78 84 86 82 85 
13 Syed ali 
Fatima 
21 83 82 91 90 82 82 80 86 78 92 93 90 91 94 
14 Mari 22 83 87 81 82 82 83 83 80 83 78 84 85 86 84 
15 Saraswathi 23 90 90 89 90 93 92 86 93 90 93 84 86 87 8681 
16 Gomathi 21 84 85 86 87 82 83 78 83 83 87 88 89 90 90 
17 Priya 25 80 92 89 93 95 98 99 100 93 100 102 99 96 92 
18 Ayisha 
begam 
26 93 95 88 82 84 78 82 81 83 86 84 80 78 84 
19 Roobini 25 94 88 84 82 92 96 95 96 93 90 91 92 88 84 
20 Selvi 26 83 88 92 92 92 89 91 94 93 72 75 76 74 78 
21 Mariammal 22 86 87 85 96 91 83 85 83 86 82 84 81 80 83 
22 Sudali 23 82 88 92 87 90 87 93 90 84 94 96 90 87 84 
23 Usha rani 20 79 81 83 82 80 83 85 80 82 83 84 86 87 86 
24 Uma 22 80 83 92 93 89 92 92 93 95 87 88 86 84 90 
25 Asha 21 83 89 93 91 95 101 99 99 98 94 95 96 91 88 
26 Dhanam 24 80 79 79 80 79 78 75 78 80 84 86 83 82 84 
27 Muthulakshmi 24 80 86 85 80 89 90 93 94 94 95 90 91 90 87 
28 Saraswathi 25 80 83 85 86 86 85 86 88 86 90 91 92 93 88 
29 Sophia 26 78 84 88 86 80 83 82 84 80 91 87 86 85 84 
30 Prema 21 84 87 88 85 86 80 84 84 92 104 106 100 102 108 
31 Banu 22 93 95 88 88 84 80 84 81 79 74 76 70 71 73 
3                 
32 Amutharani 25 70 72 77 80 76 89 88 86 86 83 86 90 90 96 
33 Maharasi 25 83 95 93 94 97 88 94 96 94 78 80 84 83 84 
34 Rabia 26 83 84 87 82 83 82 79 79 81 78 80 82 80 76 
35 Krithika 22 93 96 93 92 94 99 97 97 94 93 93 90 92 95 
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PROFORMA 
The effect of intrathecal Clonidine on post-operative analgesia in pregnant 
patients undergoing lower segment caesarian section 
 
 
Name :  Age:   Ht:   Wt: 
 
I.P.No:  Unit:   Date:  
 
Obstetric score:                  Gestational week: 
 
Type of surgery: Elective / Emergency                      ASA status: 
 
Indication: 
 
Drug history:                            dose:                            duration: 
 
Investigations: 
 
     Hb :                                 Urine albumin : 
       Blood Sugar :                                                Sugar  : 
                    Urea  :                                            deposits  : 
          Creatinine   :                                
              
O/E  
    
    Anaemia :                         Icterus  :                Edema : 
                       PR  :                                BP  : 
      
 
Pre-med: 
     Anti-emetic prophylaxis  
         Inj. Ranitidine 50mg i.v. 
        Inj. Metoclopromide 10 mg i.v. 
 
Pre-loading: I.V.Infusion of RL – 10ml / kg 
 
Anaesthesia – SAB 
 
 Position  :  Rt lateral 
 Space   :  L3 – L4 
 Needle  :  23G 
 Drug   :  B GROUP - 0.5% Bupivacaine 2ml 
C GROUP - 0.5% Bupivacaine 2ml + 75 µg Clonidine  
 
 
 
Parameters monitored  
  
VAPS 
 
Hrs 
TIME 
 
Mins. 
PR MAP 
 
mmHg 
SPO2 
 
% 
LEVEL OF 
INITIAL 
BLOCK 
2 SEG 
REG 
 
Mins. 
2 3 4 6 
TIME FOR SYSTEMIC 
ANALGESIC 
SUPPLEMENTATION 
Mins. 
5           
10           
15           
20           
30           
45           
60           
90           
120           
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